Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer, Metastatic Cancer
Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899210
- Testing
- laboratory biomarker analysis, cryosurgery, radiofrequency ablation
- Volunteers
- 75 people
- Sponsor
- University Hospital, Grenoble
Neoplasms, Colorectal, Neoplasm Metastasis
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
The main objective is to provide original research results that may change clinical practice related to metastatic colorectal cancer.
- Trial name
- NCT02395224
- Testing
- cancer treatment and follow-up according to current regional and national guidelines
- Where
- 7 sites in Norway
- Volunteers
- 354 people
- Sponsor
- Norwegian University of Science and Technology
Metastatic Colorectal Adenocarcinoma
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is…
- Trial name
- NCT07130903
- Testing
- Fruquintinib, TheraBionic P1
- Where
- 9 sites in United States
- Volunteers
- 102 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Colorectal Cancer, Recurrent Colorectal Cancer
Phase I/II Trial of Antagonism of HER in GI Cancer
Recruitment to phase I of the PANTHER trial is complete. Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
- Trial name
- PANTHER (NCT01862003)
- Testing
- AZD8931, Irinotecan, Folinic Acid
- Where
- 4 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University College, London
Colorectal Cancer Metastatic
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283303
- Testing
- T3011 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 8 people
- Sponsor
- China Medical University, China
MSS Metastatic Colorectal Cancer
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal…
- Trial name
- NCT06613113
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have…
- Trial name
- NCT07416552
- Testing
- SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Unresectable Metastatic Colorectal Cancer
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by…
- Trial name
- NCT04991948
- Testing
- CYAD-101, FOLFOX, Pembrolizumab
- Where
- 5 sites in United States, Belgium
- Volunteers
- 34 people
- Sponsor
- Celyad Oncology SA
Colon Cancer, Colorectal Cancer
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer
- Trial name
- PRECEPT (NCT00411450)
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 116 people
- Sponsor
- Amgen
Colorectal Cancer
OPTIMOX1 in Chinese mCRC Patients
Previous OPTIMOX1 study investigated the use of oxaliplatin discontinuation and reintroduction in a novel stop-and-go strategy. Previously untreated patients were randomly assigned to either FOLFOX4 administered every 2 weeks…
- Trial name
- NCT01023633
- Testing
- Oxaliplatin, LV, 5-FU
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanjing Medical University
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
NSCLC, Metastatic Colorectal Carcinoma
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts.
- Conditions
- NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
- Trial name
- NCT05061017
- Testing
- Pixatimod, Nivolumab, Cyclophosphamide (low dose)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Diwakar Davar
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
This is an open-label, multi-center, dose-finding study of tivozanib administered in combination with capecitabine. During the dose-escalation portion, sequential cohorts of subjects with advanced solid tumors will be enrolled in…
- Trial name
- NCT01306630
- Testing
- tivozanib (AV-951) and capecitabine (Xeloda®)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Colorectal Cancer, Metastatic Colorectal Cancer (CRC)
Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
The overall objective of this study is to learn whether a newly developed couple-based mindfulness program (Mindful PaCT) is practical to complete (feasible), helpful and well-received (acceptable), and relevant for patients with…
- Trial name
- NCT07759921
- Testing
- Couple-based Mindfulness Intervention, Health and Wellness Education Control Condition
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Metastatic Colorectal Cancer
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
- Trial name
- NCT05281276
- Testing
- chidamide, celecoxib
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Colon Cancer, Rectal Cancer
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT01126450
- Testing
- lenalidomide, cetuximab, mutation analysis
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in…
- Trial name
- NCT00388700
- Testing
- GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab
- Where
- 4 sites in Israel
- Sponsor
- Galectin Therapeutics Inc.
Metastatic Colorectal Cancer
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27 patients with MSS, MGMT-silenced mCRC with initial…
- Trial name
- MAYA (NCT03832621)
- Testing
- Temozolomide, Nivolumab, Ipilimumab
- Where
- Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.